23DME co -founder and former CEO Anne Wojcikki is scheduled to be repumented by the company after it has applied to protect bankruptcy, Chapter 11 earlier this year. Friday, 23andme and TTAM Institute for Research, a company with a generally non -profit interest managed by WojCICKI, Declared in a press release TTAM will buy “all the assets of the company” for $ 305 million.
As of last month, the New York Drug Technology Company was appointed to buy 23andme. For 256 million dollars. But the new purchase agreement with TTAM is “as a result of a final round of bids that occurred earlier today between TTAM and Regeneron Pharmaceuticals”, according to the statement. WoJCICKI made “unwanted offer” earlier this month, according to Wall Street Magazine.
23ndme is famous for the genome testing groups at home, and at one time the company was worth about $ 6 billion, According to CNBC. But he has not yet been able to make profit and deal with a huge data breach In 2023. The company paid $ 30 million Law of the lawsuit On the breach of last year. When 23andme submits bankruptcy In MarchWoJCICKI resigned As an executive head.
TTAM will comply with 23ndme “privacy policies and law in force”, and has provided “obligations to adopt additional protection for consumers and privacy guarantees”, including the establishment of a consumer consultative council within 90 days of the end of the deal. The statement says that the transaction is still subject to the approval of the court, but it is expected to be closed “in the coming weeks.”
